{
  "id" : "grade_post_therapy_clin_21162",
  "algorithm" : "eod_public",
  "version" : "2.1",
  "name" : "Grade Post Therapy Clin (yc)",
  "title" : "Grade Post Therapy Clin (yc)",
  "notes" : "**Note 1:** Leave post therapy grade blank when\n* No neoadjuvant therapy\n* Clinical or pathological case only\n* Neoadjuvant therapy completed, no microscopic exam is done prior to surgery/resection of primary tumor\n* There is only one grade available and it cannot be determined if it is clinical, pathological, post therapy clinical or post therapy pathological\n\n**Note 2:** Assign the highest grade from the microscopically sampled specimen of the primary site following neoadjuvant therapy or primary systemic/radiation therapy.\n* Per clarification from the CAP Cancer Committee based on the CAP Protocol, the following histologies must be assigned a G3 (code 3): Serous, clear cell, undifferentiated/de-differentiated carcinomas, carcinosarcomas, and mixed mesodermal tumors (Mullerian/MMMT) are *high risk (high grade)*\n\n**Note 3:** If there are multiple tumors with different grades abstracted as one primary, code the highest grade. \n\n**Note 4:** G3 includes anaplastic.\n\n**Note 5:** Code 9 (unknown) when \n* Microscopic exam is done after neoadjuvant therapy and grade from the primary site is not documented\n* Microscopic exam is done after neoadjuvant therapy and there is no residual cancer\n* Grade checked “not applicable” on CAP Protocol (if available) and no other grade information is available",
  "last_modified" : "2021-04-23T22:19:51.418Z",
  "definition" : [ {
    "key" : "grade_post_therapy_clin",
    "name" : "Code",
    "type" : "INPUT"
  }, {
    "key" : "description",
    "name" : "Description",
    "type" : "DESCRIPTION"
  } ],
  "rows" : [ [ "1", "G1\nFIGO Grade 1\nG1: Well differentiated" ], [ "2", "G2\nFIGO Grade 2\nG2: Moderately differentiated" ], [ "3", "G3\nFIGO Grade 3\nG3: Poorly differentiated or undifferentiated" ], [ "9", "Grade cannot be assessed (GX); Unknown" ], [ "", "See Note 1" ] ]
}